Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

• Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer
• Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist (now Merck & Co.) for $535 million in 2013

LOS ANGELES, June 12, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors. Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class operations; and forming international alliances.

After joining Pfizer, Inc. in 1971, Dr. McKinnell held positions of increasing responsibility around the world including Chairman and Chief Executive Officer from 2001 until his retirement in 2006.  In addition to his experience at Pfizer, Dr. McKinnell has served as an independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022; former Chairman/CEO of Optimer Pharmaceuticals, acquired by Cubist Pharmaceuticals (now Merck & Co.) for $535 million in 2013; independent director of ExxonMobil from 2002 to 2007; and independent director of Agiliti from 2017-2019. Most recently, Dr. McKinnell was the independent Chairman of Moody’s Corporation from 2012 to 2021.

“We are honored to have Dr. McKinnell join the Nexcella Board of Directors. He has an unparalleled track record as a pharmaceutical executive and strategic leader, with extensive experience building pre-eminent, world-class organizations,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma.  Gabriel Morris, Chief Financial Officer of ImmixBio, added, “Dr. McKinnell’s experience will be invaluable as we progress NXC-201 through clinical development in AL amyloidosis and multiple myeloma. Dr. McKinnell’s leadership and skills in our industry, as well as his contributions to other areas of human welfare, are internationally recognized. We look forward to benefiting from his valuable insights.”

Dr. McKinnell commented, “My interest and commitment to the translation of scientific discoveries to the bedside so patients can benefit makes joining the Nexcella Board an honor and hopefully the beginning of a journey which will benefit seriously ill patients around the world.”

Dr. McKinnell is the Chairman Emeritus of the Pharmaceutical Research and Manufacturers of America (PhRMA). He also served as a Senior Advisor to Toyota Motor Corporation's International Advisory Board and the Thomas H. Lee Private Equity Partnership. Dr. McKinnell holds a bachelor’s degree in business from the University of British Columbia and an M.B.A. and Ph.D. from Stanford University Graduate School of Business.

About Nexcella, Inc.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc (Nasdaq:IMMX), is a Los Angeles, CA based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our lead candidate, next generation BCMA-targeted CAR-T NXC-201 for multiple myeloma and AL amyloidosis has produced 92% and 100% response rates in each indication, respectively, as of February 9, 2023 across 58 patients. We believe NXC-201 has potential to be the world’s first outpatient CAR-T. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases. Our lead asset is IMX-110, currently in Phase 1b/2a clinical trials as a monotherapy and in its IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1, tisleilizumab, for which patient dosing begin in Feb 2023. IMX-110 holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation (RPDD) by the FDA the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPDD qualifies ImmixBio to receive fast track review and a priority review voucher (PRV) at the time of marketing approval of IMX-110. Additionally, ImmixBio subsidiary Nexcella, Inc, developing CAR-T NXC-201 for multiple myeloma and AL amyloidosis, with 92% and 100% response rates in each indication, respectively, as of February 9, 2023. Learn more at www.immixbio.com.

Forward Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Immix Biopharma, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements.

Contacts
Stern Investor Relations
Suzanne Messere
Managing Director
Suzanne.Messere@sternir.com

Company Contact
irteam@immixbio.com